Experienced in Thrombocytopenia

Yeu-chin Chen

TPQ, TW 
Experienced in Thrombocytopenia
TPQ, TW 
OverviewLocationsClinical Research

Overview

Yeu-chin Chen practices in Taiwan. Chen is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. Their top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, Von Willebrand Disease (VWD), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 54 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 8 articles in the study of Thrombocytopenia.

Locations

TPQ, Taiwan
Other Locations
No.325, Chenggong Road, Nei Hu 114, Chenggong, TPQ, Taiwan
Neihu, TPQ, Taiwan
Tainan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Biological
View 1 Less Clinical Trial

54 Total Publications

Identification of two point mutations associated with inherited antithrombin deficiency.
Identification of two point mutations associated with inherited antithrombin deficiency.
Journal: Thrombosis journal
Published: July 27, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile